Clareo Health | Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
X4 Pharmaceuticals
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have signed the current approved informed consent form. Participants under 18 years of age (in the Netherlands and other applicable regions, participants under 16 years of age) will sign an approved informed assent form and must also have a signed parental/legal guardian consent.
Have a genotype-confirmed mutation of chemokine (C-X-C motif) receptor 4 (CXCR4) consistent with WHIM phenotype.
Agree to use a highly effective form of contraception.
Be willing and able to comply with the protocol.
Have confirmed ANC ≤400 cells/µL during screening, obtained while participant has no clinical evidence of infection.
Completed the Randomized Period; or
Granted Early Release from the Randomized Period.
You may not be if
Has known systemic hypersensitivity to the mavorixafor drug substance, its inactive ingredients, or the placebo.
Is pregnant or breastfeeding.
Has any medical or personal condition, which in the opinion of the Investigator may potentially compromise the safety or compliance of the participant or may preclude the participant's successful completion of the clinical study.
